Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
704 (USA) · Dr. Tanaka
consented 2014-05-11
AEs
1
Serious
0
Dropout signal
–
Adverse events
severe
assessed
Severe COMPLETED SUICIDE — outcome: FATAL; onset 2014-10-31 (study day 174.0); relationship: NONE; serious criteria: death
Data queries
No data queries.